Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
35.8M
-
Shares change
-
+495K
-
Total reported value, excl. options
-
$264M
-
Value change
-
+$884K
-
Number of buys
-
58
-
Number of sells
-
-47
-
Price
-
$7.38
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2019
126 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q3 2019.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.8M shares
of 166M outstanding shares and own 21.63% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.2M shares), BlackRock Inc. (4.02M shares), PERCEPTIVE ADVISORS LLC (3.25M shares), VICTORY CAPITAL MANAGEMENT INC (2.62M shares), VANGUARD GROUP INC (2.61M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.21M shares), BVF INC/IL (1.88M shares), STATE STREET CORP (1.54M shares), RENAISSANCE TECHNOLOGIES LLC (1.53M shares), and RTW INVESTMENTS, LP (990K shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.